Lorundrostat Data To Be Presented At ACC.23/WCC

Mineralys Therapeutics

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), which is scheduled to take place in New Orleans, LA, on March 4-6, 2023.

Mineralys Poster Details:

Moderated Poster Title:  Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation
Presenter Name: David Rodman, MD, FAHA
Session Title: Treating the Whole Patient including Comorbidities
Presentation Number: 1029-05
Presentation Time and Date: 3:15 p.m. – 3:25 p.m. CT on Saturday, March 4, 2023
Session Location: Heart Failure and Cardiomyopathies Moderated Poster Theater 9, Hall F
Poster Presentation Title:  First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor
Presenter Name: David Rodman, MD, FAHA
Session Title: Heart Failure and Cardiomyopathies: Clinical Science 11
Presentation Number: 1560-160
Presentation Time: 12:45 p.m. – 1:30 p.m. CT on Sunday, March 5, 2023
Session Location: Poster Hall, Hall F

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  Delaware County Highways Undergo $16.9 Million Resurfacing: Motorists Face Nightly Delays